Pregnancy Clinical Trial
— FAZSTOfficial title:
Folic Acid and Zinc Supplementation Trial: A Multi-center, Double-blind, Block-randomized, Placebo-controlled Trial
NCT number | NCT01857310 |
Other study ID # | FAZST |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2013 |
Est. completion date | June 2019 |
The overarching goal of this trial is to determine if an intervention comprising folic acid and zinc dietary supplementation improves semen quality and indirectly fertility outcomes (i.e., live birth rate) among couples trying to conceive and seeking assisted reproduction. The following study objectives underlie successful attainment of the overarching research goal: 1. To estimate the effect of folic acid and zinc dietary supplementation on semen quality parameters, including but not limited to concentration, motility, morphology, and sperm DNA integrity, relative to the placebo group. 2. To estimate the effect of folic acid and zinc dietary supplementation on fertility treatment outcomes [fertilization, embryo quality, implantation/human Chorionic Gonadotropin (hCG) confirmed pregnancy, clinical pregnancy, live birth], relative to the placebo group. 3. To estimate the association between semen quality parameters, sperm DNA integrity and fertility treatment outcomes (fertilization, embryo quality, clinical pregnancy, live birth) and to identify the best combination of semen quality parameters for prediction of clinical pregnancy and live birth. 4. To estimate the effect of folic acid and zinc dietary supplementation on fertilization rates among couples undergoing assisted reproductive technology procedures, relative to the placebo group. 5. To estimate the effect of folic acid and zinc dietary supplementation on embryonic quality among couples undergoing assisted reproductive technology procedures, relative to the placebo group.
Status | Completed |
Enrollment | 2370 |
Est. completion date | June 2019 |
Est. primary completion date | June 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Couples Inclusion Criteria: 1. Heterosexual couples in a committed relationship with a female partner aged 18-45 years and male partner aged 18 years and older attempting to conceive and seeking assisted reproduction at participating fertility clinics. 2. Couples actively trying to conceive. 3. Couples who are planning ovulation induction (OI), natural fertility optimization methods, or intrauterine insemination (IUI) should be willing to be on the study dietary supplement for at least 3 weeks before starting the next assisted reproduction cycle.Women with regular periods may initiate their fertility therapy at the start of the woman's menstrual cycle following randomization if randomization occurred within the first 10 days of the cycle, but must wait one menstrual cycle if the visit occurred after day 10 of the cycle). For women with irregular periods or amenorrhea, the male must be on the study supplement for 3 weeks prior to initiation of any ovulation induction medication (e.g., clomid, letrozole, gonadotropins). Couples Exclusion Criteria: 1. Female partner unwilling to participate (e.g., no abstraction of her assisted fertility treatment record or unwilling to complete baseline visit). 2. Couples using donor, cryopreserved sperm, or sperm obtained via microsurgical or percutaneous epididymal sperm aspiration. 3. Couples attempting to conceive with a gestational carrier (surrogate). 4. Positive urine pregnancy test at screening. Male Inclusion Criteria: 1. Willing to provide semen samples according to the proposed schedule at baseline, 2, 4, and 6 months of follow-up. 2. Able to complete regular study questionnaires and daily journals aimed at capturing ejaculation, sexual intercourse and lifestyle factors considered to affect male fecundity (e.g., cigarette smoking, fever, high temperature environment and other environmental exposures) and other data collection instruments (e.g., physical activity, food frequency questionnaire, stress). Male Exclusion Criteria: 1. Age <18 years. 2. Unwilling to abstain from use of non-study approved dietary supplements or medications containing folic acid or oral preparations containing zinc throughout the study. 3. Unwilling to abstain from use of testosterone supplementation throughout the study. 4. Diagnosis of Vitamin B12 deficiency or pernicious anemia. 5. Consuming a vegan diet. 6. A known genetic cause of male factor subfertility, including chromosomal disorders related to subfertility (e.g., Y chromosome deletions). 7. Males currently using and unwilling (or unable) to discontinue the following drugs known to interact with folic acid or interfere with the biosynthesis of folic acid will be excluded. 1. Dihydrofolate reductase inhibitors: Trimethoprim, Triamterene, Bactrim, Iclaprim 2. Sulfonamides: Hydrochlorothiazide (HCTZ), Metolazone, Indapamide, Lasix, Bumex, Torsemide, Chlorthalidone, Acetazolamide, Mefruside, Xipamide 3. Sulfonylureas: Glipizide, Glyburide 4. Cox-2 inhibitors: Celecoxib 5. Others: Valproic acid, Probenecid, Sulfasalazine, Sumatriptan, Mafenide, Ethoxzolamide, Sulfiram, Zonisamide, Dorzolamide (optic), Dichlorphenamide, Fluorouracil, Capecitabine, Methotrexate 8. History of organ transplantation. 9. Physician diagnosed: 1. Current poorly controlled chronic diseases such as heart disease, diabetes mellitus, hypertension, cancer, inflammatory diseases, autoimmune, thyroid disease, endocrine dysfunction, liver disease, kidney disease, or HIV/AIDS or other immune-insufficient related illnesses. 2. Crohn's disease, celiac disease, ulcerative colitis, gastric bypass surgery, lap band surgery or history of intestinal surgery to remove a portion of small bowel. History of diseases/symptoms that require folic acid dietary supplementation, such as megaloblastic anemia, homocystinemia, and homocystinuria. 3. History of alcohol dependency disorder and/or other drug/substance dependency in the past 180 days. 4. History of psychoses or other mental conditions that would result in cognitive impairment and inability to participate in any part of this study including the informed consent process, as diagnosed by a physician within the past year. 10. History of vasectomy without reversal, obstructive azoospermia such as Congenital Bilateral Aplasia of Vas Deferens (CBAVD), or ejaculatory duct obstruction. 11. Known allergy to folic acid or zinc dietary supplements. Female Exclusion Criteria: Age <18 or >45 years. |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University | Chicago | Illinois |
United States | University of Iowa | Iowa City | Iowa |
United States | Center for Reproductive Medicine | Minneapolis | Minnesota |
United States | University of Utah | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Reproductive Hormones and Other Measured Biomarkers | Urinary, serum, and salivary concentrations of reproductive hormones, particularly androgens, proteomic analysis of human sperm and cardiometabolic risk factors and markers of oxidative stress, as well as measures of trace elements in toenails (collected at month 4 clinic visit). Biospecimens have been collected but laboratory analysis still needs to be done to be able to evaluate these endpoints. | 4 or 6 months | |
Primary | Live Birth | Based on hospital delivery records | At delivery | |
Primary | Semen Volume | Volume of the ejaculate, mL Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010. | 6 months | |
Primary | Sperm Concentration | Number of spermatozoa per unit of volume of semen Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010. | 6 months | |
Primary | Sperm Motility | % motile (including percentage of progressive motile sperm and percentage of nonprogressive motile sperm) Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010. | 6 months | |
Primary | Sperm Morphology | % normal morphology Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010. | 6 months | |
Primary | DNA Fragmentation Index | Comet assay used to measure sperm DNA integrity based on excess DNA strand breaks Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010. | 6 months | |
Primary | Total Motile Sperm Count | Calculated as semen volume (mL) * sperm concentration (10^6 spermatozoa/mL) * motility (% motile) | 6 months | |
Secondary | Human Chorionic Gonadotropin (hCG) Detected Pregnancy (Implantation) | A quantitative hCG evaluation in serum > 5 milli-international units per milliliter (mIU/ml) | For IVF, 12 days post embryo transfer for day 5 embryo transfers, and 14 days post embryo transfer for day 3 embryo transfers; for couples undergoing OI/IUI, after self-report of positive pregnancy test | |
Secondary | Clinical Intrauterine Pregnancy | Visualized gestational sac in the uterus on ultrasound | approximately 6.5 weeks gestation | |
Secondary | Ectopic Pregnancy | Either visualization of no gestational sac in the uterus with a suspicious mass in the adnexa on ultrasound, an hCG level more than 1500 mIU/ml without visualization of an intrauterine gestational sac on ultrasound, or a slowly rising or plateauing serum hCG level without visualization of an intrauterine gestation on ultrasound. | approximately 6.5 weeks gestation | |
Secondary | Early Pregnancy Loss | hCG pregnancy loss will be defined as a serum hCG > 5 mIU/ml followed by a decline. Clinically recognized pregnancy losses will be defined as visualization of an intrauterine gestational sac followed by a loss prior to 20 weeks gestation. | hcG-detected pregnancy until 20 weeks of pregnancy | |
Secondary | Preeclampsia or Gestational Hypertension | Abstracted from hospital records and medical charts | Delivery | |
Secondary | Gestational Diabetes | Abstracted from hospital records and medical charts | Delivery | |
Secondary | Cesarean Delivery | Abstracted from hospital records and medical charts | Delivery | |
Secondary | Preterm Delivery | Abstracted from hospital records and medical charts | Delivery | |
Secondary | Small for Gestational Age | Abstracted from hospital records and medical charts | Delivery | |
Secondary | Gestational Age | Abstracted from hospital records and medical charts | Delivery | |
Secondary | Birth Weight | Abstracted from hospital records and medical charts | Delivery | |
Secondary | Stillbirth | Loss at or after 20 weeks gestation. Determined based on hospital records and medical chart abstraction. | Delivery | |
Secondary | Neonatal Mortality | Abstracted from hospital records and medical charts | Delivery | |
Secondary | Major Neonatal Complications | Abstracted from hospital records and medical charts: includes bronchopulmonary dysplasia, necrotizing enterocolitis, severe intraventricular hemorrhage, periventricular leukomalacia, and retinopathy of prematurity | Delivery | |
Secondary | Structural Malformations | Abstracted from birth record: includes major (n = 21; 6 with known genetic cause), minor (n = 6), and unclassified (n = 2) defects Structural birth defects: includes hydronephrosis/ureteropelvic junction obstruction, transposition of the great arteries, renal agenesis, cleft lip, club feet, multicystic/dysplastic kidney, tetralogy of fallot, gastroschisis, atrioventricular septal defects, other oral-facial defects, other cardiovascular defects, other CNS defects, other eye defects, other oral-facial defects, other anomalies, other syndromes | Delivery | |
Secondary | Severe Maternal Morbidity | Abstracted from delivery record: including postpartum hemorrhage, anemia requiring transfusion, sepsis, seizure, HELLP syndrome or preeclampsia with pulmonary edema | Delivery | |
Secondary | Fertilization Rate Per Cycle, % | Among participants in the IVF stratum Oocytes will be assessed 16-18 hours after insemination or microinjection to determine whether fertilization occurred. Fertilization will be considered normal if two pronuclei and two polar bodies are identified. Oocytes without visible pronuclei will be considered unfertilized. Oocytes with more than two pronuclei will be considered abnormally fertilized, and will thus be discarded. | Up to 9 months of fertility treatment post-randomization | |
Secondary | Number of Good Quality Embryos on Day 5 Per Cycle | Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria. | Up to 9 months of fertility treatment post-randomization | |
Secondary | Percentage of Good Quality Embryos on Day 5 Per Cycle | Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria. | Up to 9 months of fertility treatment post-randomization | |
Secondary | Number of Embryos Transferred Per Cycle | Among participants in the IVF stratum | Up to 9 months of fertility treatment post-randomization | |
Secondary | Number of Embryos Cryopreserved Per Cycle | Among participants in the IVF stratum | Up to 9 months of fertility treatment post-randomization | |
Secondary | Sperm Penetration Per Cycle, % | Among participants in the IVF stratum | Up to 9 months of fertility treatment post-randomization | |
Secondary | Cells on Day 3 Per Embryo Per Cycle | Among participants in the IVF stratum | Up to 9 months of fertility treatment post-randomization | |
Secondary | Cells on Day 3 Per Embryo Per Cycle, Categorical | Number of cells per embryo among women in the IVF stratum | Up to 9 months of fertility treatment post-randomization | |
Secondary | Cells on Day 5 Per Embryo Per Cycle, Categorical | Among participants in the IVF stratum | Up to 9 months of fertility treatment post-randomization | |
Secondary | Embryo Morphology on Day 3 Per Cycle, Categorical | Among participants in the IVF stratum Embryos will be scored three days after fertilization according to the size and shape of blastomeres and to their degree of fragmentation.
Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci 1988;541:259-74.:259-74. |
Up to 9 months of fertility treatment post-randomization | |
Secondary | Embryo Morphology on Day 5 Per Cycle, Categorical | Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria. | Up to 9 months of fertility treatment post-randomization | |
Secondary | Method of Fertilization Per Cycle | Among participants in the in vitro fertilization (IVF) stratum: method of fertilization classified into intracytoplasmic sperm injection (ICSI) and other | Up to 9 months of fertility treatment post-randomization | |
Secondary | Quality of Embryos Transferred Per Cycle, Categorical | Among participants in the IVF stratum Embryonic grading based on Society for Assisted Reproductive Technologies (SART) morphology criteria | Up to 9 months of fertility treatment post-randomization | |
Secondary | Chromosomal Complement of Embryo Per Cycle | Among participants in the IVF stratum Chromosomal complement in the embryo assessed using methodology cited by Rubio et al.
Rubio C, Rodrigo L, Mir P et al. Use of array comparative genomic hybridization (array-CGH) for embryo assessment: clinical results. Fertil Steril 2013 March 15;99(4):1044-8. |
Up to 9 months of fertility treatment post-randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Completed |
NCT02520687 -
Effects of Dietary Nitrate in Hypertensive Pregnant Women
|
Phase 1 |